ImmunityBio Past Earnings Performance
Past criteria checks 0/6
ImmunityBio's earnings have been declining at an average annual rate of -27.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 47.8% per year.
Key information
-27.4%
Earnings growth rate
-22.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -47.8% |
| Return on equity | n/a |
| Net Margin | -93,761.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
Apr 23ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11ImmunityBio: PDUFA Pending
Oct 17ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Aug 07ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
Jun 02ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter
Mar 15ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat
Dec 27ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
Oct 12ImmunityBio: Market Has Lost Contact Following Merger
Jul 19ImmunityBio posts results from early-stage blood cancer study
May 04Revenue & Expenses BreakdownBeta
How ImmunityBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -583 | 135 | 227 |
| 30 Sep 23 | 1 | -458 | 123 | 238 |
| 30 Jun 23 | 1 | -473 | 111 | 262 |
| 31 Mar 23 | 1 | -430 | 95 | 272 |
| 31 Dec 22 | 0 | -417 | 109 | 242 |
| 30 Sep 22 | 1 | -400 | 93 | 241 |
| 30 Jun 22 | 1 | -376 | 103 | 218 |
| 31 Mar 22 | 1 | -370 | 119 | 209 |
| 31 Dec 21 | 1 | -347 | 127 | 192 |
| 30 Sep 21 | 0 | -323 | 124 | 186 |
| 30 Jun 21 | 0 | -301 | 112 | 174 |
| 31 Mar 21 | 1 | -264 | 97 | 154 |
| 31 Dec 20 | 1 | -222 | 61 | 140 |
| 30 Sep 20 | 2 | -176 | 56 | 110 |
| 31 Dec 19 | 2 | -158 | 46 | 112 |
| 31 Dec 18 | 3 | -84 | 29 | 47 |
Quality Earnings: IBRX is currently unprofitable.
Growing Profit Margin: IBRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBRX is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.
Accelerating Growth: Unable to compare IBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IBRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.